Clinical trial NCT01344707: Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)
Official title: Open Label, Dose Escalation Study of 4SC-202 in Patients With Advanced Hematologic Malignancies: First-In-Man Study of a Newly Developed, Oral Histone Deacetylase Inhibitor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Hematologic Malignancies
Keywords: Hematologic Malignancies
Acute Myeloid Leukemia (AML)
Acute Lymphocytic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma (MM)
Myelodysplastic Syndrome (MDS)
Malignant Lymphomas
Histone Deacetylase (HDAC)
4SC-202
Phase I
Lead sponsor: 4SC AG
Sponsor class: INDUSTRY
First posted: 2011-04-29
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the Maximum Tolerated Dose, Dose Limiting Toxicities and optimal dosing schedule of 4SC-202 investigating its safety, tolerability and pharmacokinetics.


Eligibility criteria: Inclusion Criteria:

* Male or female patients, age ≥ 18 years.
* Patients with Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM),Myelodysplastic Syndrome (MDS) or malignant lymphoma which are relapsed and/or refractory to standard therapy or for which no standard therapy exists. Patients who are not eligible for curative stem cell transplantation or patients who have refused or are not eligible for frontline (chemo-) therapy may also be included.
* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.
* Patients must have a live expectancy of 12 weeks or more.
* Patients must have adequate bone marrow reserve as well as adequate renal and hepatic function and serum electrolytes within a clinically acceptable range.
* Patients must have recovered from any treatment-related toxicities (to Grade 0 or 1 according to Common Terminology Criteria for Adverse Events (CTCAE); except for alopecia, fatigue and Grade 1 neurotoxicity) prior to registration.

Exclusion Criteria:

* Patients who have received previous treatment with an HDAC inhibitor.
* Patients with any gastrointestinal disorder that could interfere with the absorption of 4SC-202
* Patients who are unable to take oral medication.
* Patients with a history of other malignancies unless having undergone definitive treatment more than 5 years prior to entry into the study and without evidence of recurrent malignant disease, excluding patients with basal cell carcinoma of the skin; superficial carcinoma of the bladder; carcinoma of the prostate with a current prostate specific antigen (PSA) value of \< 0.1 ng/ml; or cervical intraepithelial neoplasia.
* Patients with a history of, who were treated for, or who are suspected of having, hepatitis B, hepatitis C or human immunodeficiency virus (HIV). Patients suspected of having any of these conditions should undergo appropriate evaluations prior to being enrolled in the study.
* Patients with precedent anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the last two weeks or a longer period depending on the known PK characteristics of the agents used.
* Patients with history or current evidence of clinically relevant allergies or idiosyncrasy to drugs (especially of similar chemical composition to the study drug) or food.
* Patients with symptomatic brain metastases/central nervous system (CNS) involvement.
* Patients with significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension, congestive heart failure (New York Heart Association (NYHA) Class III or IV) related to primary cardiac disease, a condition requiring anti-arrhythmic therapy, ischemic or severe valvular heart disease, or a myocardial infarction within 6 months prior to the trial entry.
* Patients with a marked baseline prolongation of QT/QTc interval, e.g., repeated demonstration of a QTc interval \> 450 msec (Grade 1 CTCAE); Long-QT-Syndrome; the required use of concomitant medication on 4SC-202 dosing days that may cause Torsade de Pointes.
* Therapy with agents known to prolong the QT interval, such as certain antibiotics (i.e. erythromycin, clarithromycin), antidepressants (i.e. doxepin, amitryptilin) or neuroleptics (i.e. haloperidol, clozapin).

Primary outcomes:
measure: Determination of Dose Limiting Toxicities of 4SC-202
timeFrame: 6 weeks
measure: Determination of Safety of 4SC-202
timeFrame: 6 weeks
measure: Determination of Pharmacokinetic Profile of 4SC-202
timeFrame: 3 weeks
measure: Determination of Maximum Tolerated Dose of 4SC-202
timeFrame: 6 weeks
measure: Determination of Tolerability of 4SC-202
timeFrame: 6 weeks
Secondary outcomes:
measure: Assessment of potential anticancer activity of 4SC-202
timeFrame: 6 weeks
measure: Histone deacetylase (HADAC) inhibition in peripheral mononuclear cells
timeFrame: 6 weeks
measure: Histone acetylation in peripheral mononuclear cells
timeFrame: 6 weeks
measure: Gene expression analysis in peripheral blood
timeFrame: 6 weeks
measure: Cytokine and miRNA levels in plasma
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Köln
country: Germany
facility: Universiätsklinikum Köln
city: Stuttgart
country: Germany
facility: Robert-Bosch-Krankenhaus
city: Würzburg
country: Germany
facility: Universitätsklinikum Würzburg
Study officials:
affiliation: Universitätsklinikum Köln
name: Andreas Engert, Prof. MD
role: PRINCIPAL_INVESTIGATOR
References: